Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021, The Lancet Respiratory Medicine, October 18, 2024

In a large study published on the The Lancet Respiratory Medicine on October 18, 2024, epidemiological and vital registry data were analysed to estimate the non-fatal and fatal burden of pulmonary arterial hypertension, using standard GBD (Global Burden of Diseases) modelling approaches. 🔹 The aim of this investigation was to better characterise the worldwide epidemiology […]

Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021, The Lancet Respiratory Medicine, October 18, 2024 Read Post »

The global burden of pulmonary arterial hypertension: profound but improving?, The Lancet Respiratory Medicine, October 18, 2024

An article titled “The global burden of pulmonary arterial hypertension: profound but improving?”, was published on October 18, 2024, on the The Lancet Respiratory Medicine. The authors are Joe Newman,Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK, Department of Medicine, University of Cambridge, Cambridge, UK and Joanna Pepke-Zaba, Pulmonary Vascular Disease Unit, Royal Papworth

The global burden of pulmonary arterial hypertension: profound but improving?, The Lancet Respiratory Medicine, October 18, 2024 Read Post »

From Dr. Google to Dr. ChatGPT: Evaluating the Credibility of ChatGPT for Pulmonary Arterial Hypertension Information

Patients worldwide are increasingly switching from Dr. Google to Dr. Chat GPT. A recent article titled “Trustworthiness, Value, Danger, and Readability of ChatGPT-Generated Responses to Health Questions Related to Pulmonary Arterial Hypertension”, published in the Cureus Journal of Medical Science on October 14, 2024, aimed to determine how well ChatGPT could accurately and consistently respond

From Dr. Google to Dr. ChatGPT: Evaluating the Credibility of ChatGPT for Pulmonary Arterial Hypertension Information Read Post »

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States, Pharmacoeconomics, October 12, 2024

A study published on Pharmacoeconomics on October 12 reveals that pulmonary arterial hypertension continues to be associated with a very high economic burden and healthcare resource utilization across all payer types within the US healthcare system. The study included 11,670 patients enrolled in Medicare Fee-for-Service, 1,021 patients enrolled in Medicare Advantage, 274 patients enrolled in

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States, Pharmacoeconomics, October 12, 2024 Read Post »

New research published in “The Lancet” suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, September 19, 2024

New research published in The Lancet on September 19, 2024, suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies up to now

New research published in “The Lancet” suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, September 19, 2024 Read Post »

“The Aristotle Classes on Pulmonary Hypertension (PH) and Adult Congenital Heart Disease (ACHD)”, October 12, 2024, Thessaloniki, Greece

The President of the Greek patient association Hellenic Community for pulmonary hypertension and of the Alliance for Pulmonary Hypertension Ioanna Alysandratou Ιωάννα Αλυσανδράτου was invited to address the “Aristotele classes on pulmonary hypertension (PH) and congenital heart disease (CHD)” congress on the 12th of October 2024. Her participation is important as it brings the vital

“The Aristotle Classes on Pulmonary Hypertension (PH) and Adult Congenital Heart Disease (ACHD)”, October 12, 2024, Thessaloniki, Greece Read Post »

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation , October 4, 2024: a state-of-the-art review which summarizes the current understanding of the mechanism of action of sotatercept, the impact on outcomes that improve how patients feel, function, and survive, and the safety and

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024 Read Post »

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024

A new study published in Acta cardiologica on October 4, 2024, reviews the current evidence on sotatercept and provides a Belgian perspective on its place in the future treatment strategy for pulmonary arterial hypertension. We are delighted to see that two patients from Belgium are included as co-authors. Wendy Vansteenkiste is the President of the

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024 Read Post »

Beyond Provision: A Multidimensional View of Access to Health Care for Rare Diseases, The Lancet Global Health, October 2024

Access to health care is a broad and complex topic that warrants a clearer definition. What does is actually mean? Is it simply the provision of health services and medicines? An article titled “Access in the rare diseases landscape”, published in The Lancet Global Health October 2024 edition, delves into the different aspects that define

Beyond Provision: A Multidimensional View of Access to Health Care for Rare Diseases, The Lancet Global Health, October 2024 Read Post »

The RHU DESTINATION 2024 project to enhance the care of chronic thromboembolic pulmonary hypertension (CTEPH) patients through better identification and management

🔹 The RHU DESTINATION 2024 is a multidisciplinary partnership that aims to revolutionise the care of patients through better identification and management of chronic thromboembolic pulmonary hypertension, as well as by improving the quality of care and developing a “treat to cure” approach. 🔹 Coordinated by AP-HP, Assistance Publique – Hôpitaux de Paris, and bringing

The RHU DESTINATION 2024 project to enhance the care of chronic thromboembolic pulmonary hypertension (CTEPH) patients through better identification and management Read Post »

The European Lung Foundation (ELF)’s 2023 Annual Report highlights its ongoing efforts to to collaborate with patients, patient organisations, healthcare professionals and the public

The Alliance for Pulmonary Hypertension is a proud member of the European Lung Foundation (ELF) Patient Organisation Network and is represented in the European Lung Foundation Pulmonary Hypertension Patient Advisory Group (PH PAG). The European Lung Foundation Patient Advisory Groups and working groups are made up of people who have an interest in a particular

The European Lung Foundation (ELF)’s 2023 Annual Report highlights its ongoing efforts to to collaborate with patients, patient organisations, healthcare professionals and the public Read Post »

New research suggests that the serotonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, The Lancet Respiratory Medicine, September 19, 2024

The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies have yielded mixed results. New research published in The Lancet suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. ELEVATE-2 was a

New research suggests that the serotonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

Medication adherence in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), European Respiratory Review, September 2024

An article titled “Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review”, was recently published in the European Respiratory Review. It investigates medication adherence (MA) in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The authors note that while it

Medication adherence in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), European Respiratory Review, September 2024 Read Post »

New study finds that elevated “asporin” levels in pulmonary arterial hypertension lung samples are linked to lower disease severity, Healio news, October 2, 2024

In pulmonary arterial hypertension lung samples researchers have observed elevated asporin levels and found a link between these levels and lower disease severity. Higher levels of asporin appeared to counteract the pathological remodeling of the pulmonary vasculature that characterizes pulmonary arterial hypertension. Jason Hong, MD, PhD, assistant clinical professor at David Geffen School of Medicine

New study finds that elevated “asporin” levels in pulmonary arterial hypertension lung samples are linked to lower disease severity, Healio news, October 2, 2024 Read Post »

Results of the INSIGNIA-PAH study on MK-5475, an inhaled soluble guanylate cyclase stimulator for pulmonary arterial hypertension, published on the ERS Respiratory Journal, Vol 64 Issue 3, 2024

MK-5475 is an experimental soluble guanylate cyclase stimulator which is administered via dry powder inhalation and is designed to potentially mitigate the side effects associated with systemic vasodilation. The results of the INSIGNIA-PAH study published in the Respiratory Journal suggest that MK-5475 reduced pulmonary vascular resistance (PVR) and was well tolerated in patients with pulmonary

Results of the INSIGNIA-PAH study on MK-5475, an inhaled soluble guanylate cyclase stimulator for pulmonary arterial hypertension, published on the ERS Respiratory Journal, Vol 64 Issue 3, 2024 Read Post »

Patient centered care at the heart of The Transplantation Society’s Annual Congress in Istanbul, 22-25 September 2024

The 30th The Transplantation Society (TTS) Annual Congress in Istanbul brought together over 2.500 transplant professionals from 90 countries, with a further 500 attending remotely. It began with a memorable opening ceremony, attended by prominent figures such as the Minister of Health, the Governor, and the Mayor of Istanbul. The ceremony featured a compelling speech

Patient centered care at the heart of The Transplantation Society’s Annual Congress in Istanbul, 22-25 September 2024 Read Post »

Single tablet combination macitentan and tadalafil for pulmonary arterial hypertension (PAH) receives EU Commission approval, September 30, 2024

Janssen-Cilag International NV, a Johnson & Johnson company, announced on September September 30, 2024, that the European Commission has approved Yuvanci®, a single tablet macitentan 10 mg and tadalafil 40 mg combination therapy for the long-term treatment of adult pulmonary arterial hypertension patients in WHO Functional Class II-III, who are treated with macitentan and tadalafil

Single tablet combination macitentan and tadalafil for pulmonary arterial hypertension (PAH) receives EU Commission approval, September 30, 2024 Read Post »

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024

Article exploring the serotonin pathway in pulmonary arterial hypertension care published in The Lancet Respiratory Medicine on September 19, 2024, titled “Serotonin pathway blockade in pulmonary arterial hypertension”. The author is Marcin Kurzyna, MD, PhD, FESC Citation Serotonin pathway blockade in pulmonary arterial hypertension, Kurzyna, Marcin, The Lancet Respiratory Medicine, Volume 0, Issue 0, DOI: 10.1016/S2213-2600(24)00291-1

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

TRANSLATE »
Scroll to Top